Idorsia's rival to Merck's insomnia drug clears phase 3 test

A phase 3 trial of Idorsia’s daridorexant in insomnia patients has met its primary endpoint. The Swiss biotech, which was created through Johnson & Johnson’s takeover of Actelion, also linked the dual orexin receptor antagonist to improvements in daytime performance, sending its share price up 12%.

Idorsia's rival to Merck's insomnia drug clears phase 3 test
A phase 3 trial of Idorsia’s daridorexant in insomnia patients has met its primary endpoint. The Swiss biotech, which was created through Johnson & Johnson’s takeover of Actelion, also linked the dual orexin receptor antagonist to improvements in daytime performance, sending its share price up 12%.